14 results about "Antitumor immunity" patented technology

Lung cancer remains the leading cause of cancer-related deaths in the world. Despite the fact that introduction of immune checkpoint inhibitors (ICIs) led to a major advancement in lung cancer treatment, disease prognosis continues to remain low and a significant proportion of patients do not respond to such therapies. Cancer vaccines could potentially provide a complementary approach to boost antitumor immunity and act synergistically with ICIs. Novel tumor antigens shared by a large proportion of lung tumor cells are described herein. Several of the tumor antigens described herein derive from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells and vaccines derived from these tumor antigens are described. The use of the tumor antigens, nucleic acids, compositions, cells and vaccines for the treatment of lung cancer is also described.

The present invention provides an improved oncolytic virus that enhances collateral cell killing and induces anti-tumor immunity. The oncolytic virus comprises an oncolytic herpesvirus backbone genetically modified to encode a tumor cell-binding component and an immunoglobulin (Ig)-binding component. For example, the present invention provides an improved oncolytic virus comprising an oncolytic virus backbone genetically modified to encode a chimeric molecule comprising a tumor cell-binding component and an immunoglobulin (Ig)-aggregating component and to induce secretion of the chimeric molecule from infected cells, wherein the secreted chimeric molecule enhances collateral tumor cell killing and anti-tumor immunity in the presence of anti-viral antibodies or other Ig and innate immune cells.

The invention belongs to the technical field of medicines, and particularly relates to an application of oleanolic acid in tumor resistance, and the application of oleanolic acid in tumor resistance specifically comprises the following steps: inhibiting tumor cell proliferation and inducing apoptosis; tumor angiogenesis is inhibited; the drug resistance of tumor cells is reversed; the immune function is regulated, and the anti-tumor immunity is enhanced; tumor invasion and metastasis are inhibited; according to the method, supercritical CO2 extraction is adopted, recoverable CO2 is used as an extraction medium, and no toxic organic solvent such as chloroform is used in the whole process; a small amount of ethanol is used only in the links of resin activation and elution, and is recovered through vacuum concentration, so that the use amount is extremely small, the treatment is easy, and the environmental pollution caused by solvent leakage or residue is avoided from the source.

Pharmaceutical compositions of the invention comprise functionalized benzamide derivatives useful as cyclic GMP-AMP synthase-Stimulator of interferon gene (cGAS-STING) pathway agonists, and useful for treating viral diseases and boost antitumor immunity.

The application discloses application of TRIM33 and miR-BART8-3p as target points in preparation of a drug for advanced nasopharyngeal carcinoma. The application first discloses that in the advanced nasopharyngeal carcinoma, EBV encoded miR-BART8-3p directly targets and inhibits the expression of TRIM33, up-regulates the expression of PD-L1, and finally promotes the molecular mechanism of immune escape. This discovery is particularly aimed at patients with advanced metastatic nasopharyngeal carcinoma, and fills the blank of the mechanism research of immunotherapy drug resistance of the population. Therefore, by up-regulating TRIM33 or inhibiting miR-BART8-3p, the antitumor immunity of the patient with advanced nasopharyngeal carcinoma can be effectively regulated, and a new strategy for treating advanced nasopharyngeal carcinoma, reversing immunotherapy drug resistance and enhancing the curative effect of a PD-1 inhibitor is formed. The application provides a complete solution from mechanism research to treatment application and precise prediction for the advanced nasopharyngeal carcinoma.

This invention discloses a sodium ion-responsive injectable self-assembled hydrogel system, its preparation method, and its applications. Specifically, it involves in vitro and in vivo experimental studies on the loading and delivery capacity, attenuation capacity, and enhancement of immunotherapeutic and antitumor efficacy of 1,6-DAS hydrogel for oncolytic bacteria. Through molecular biology experiments, pharmacodynamic experiments, flow cytometry, and molecular dynamics simulations, it elucidates the mechanisms by which the 1,6-DAS hydrogel achieves further attenuation of oncolytic bacteria, enhanced antitumor immunity, and improved efficacy without affecting the inherent targeted antitumor activity of oncolytic bacteria. This invention belongs to the field of biotechnology. By combining innovative materials with live bacteria, it systematically elucidates the key effects and corresponding mechanisms of 1,6-DAS hydrogel-loaded oncolytic bacteria administration on their toxicity and efficacy, providing direct practical evidence for the wider application of 1,6-DAS hydrogel in the field of in vivo microbial therapy.

This application relates to the use of hydroxyphenylpropanoate compounds of formula (I), (II), (III), (IV), or (V), or pharmaceutically acceptable salts, solvates, and / or ester prodrugs thereof, compositions comprising the same, and their use in, for example, cancer immunotherapy, for increasing antitumor immunity. More particularly, this application relates to compounds useful in the treatment of diseases, disorders, or conditions that can be treated by increasing intracellular antitumor immunity, such as cancer.

Compounds can specifically activate TLR7. The compounds are useful because they can stimulate innate immunity. The compounds can be used in the treatment of conditions including cancer, viral infections and skin lesions. The compounds can optionally be formulated for enhanced penetration following topical administration, the composition preferably initiating a local specific inflammatory cytokine response while limiting undesirable erythema and other inflammatory reactions. Pharmaceutical compositions contain the compound and preferably an additional compound such as imiquimod and / or resiquimod (R848). A composition contains the compound and a compound can be used as a medicament. Other aspects, embodiments, advantages and applications will become clear from the further description herein.

The invention discloses a hydrogel-based bionic three-level lymph node and a preparation method and application thereof. According to the bionic three-level lymph node, hydrogel is used as a stent, and drug-loaded lipid nanoparticles modified by a tumor targeting group are loaded in the hydrogel stent. The hydrogel-based bionic three-level lymph node disclosed by the invention can be used for in-situ gelling beside a tumor tissue, so that an anti-tumor drug is further slowly released. After tumor cells are killed, tumor-associated antigens and injury-associated molecular patterns released by the tumor cells can be adsorbed into the hydrogel. The adsorbed components enhance the collection and activation of immune cells by the hydrogel system, and the generated anti-tumor immunity can further kill tumor cells.

Compositions containing lipid nanoparticles and nucleic acid therapeutic agents are disclosed. For example, calcium phosphate nanoparticles having a lipid coating are provided, wherein the calcium phosphate nanoparticles include a cyclic dinucleotide and the lipid coating includes phosphatidylserine. The compositions can be formulated for administration to the lungs of a subject via inhalation, or for administration via injection. Methods for the treatment of lung cancer and other cancers are also described. Targeted delivery of therapeutic agents such as cyclic dinucleotides to antigen presenting immune cells via the disclosed methods can elicit beneficial antitumor immunity.

This invention discloses an engineered bacterial strain with strong tumor targeting and controllable intratumoral drug expression, its preparation method, and its applications. An ST engineered bacterial strain stably expressing OmpA-SpyTag on its outer membrane was obtained through genetic modification. A SpyCatcherΔ-targeting peptide fusion protein (e.g., multiple targeting peptide 4×RGD) was conjugated to its surface to obtain an ST / SC-targeting peptide engineered bacterial strain. This engineered strain, under the recognition and adhesion of the targeting peptide, is efficiently retained in tumor tissue while greatly avoiding off-target migration to healthy organs. The strain colonizing the tumor can continuously proliferate and induce intratumoral expression of antitumor protein drugs through quorum sensing, including: HtrA protein expression to enhance extracellular polysaccharide-mediated immunogenicity and activate immune cells; and therapeutic nanobody expression to synergistically enhance antitumor immunity. This method achieves durable and potent tumor suppression through targeted immune remodeling. This engineered bacterium can achieve more efficient, durable, and safe tumor-targeted therapy.

The present invention is based on the seminal discovery that targeted immunomodulatory antibodies and fusion proteins can counter act or reverse immune tolerance of cancer cells. Cancer cells are able to escape elimination by chemotherapeutic agents or tumor-targeted antibodies via specific immunosuppressive mechanisms in the tumor microenvironment and such ability of cancer cells is recognized as immune tolerance. Such immunosuppressive mechanisms include immunosuppressive cytokines (for example, Transforming growth factor beta (TGF-β)) and regulatory T cells and / or immunosuppressive myeloid dendritic cells (DCs). By counteracting tumor-induced immune tolerance, the present invention provides effective compositions and methods for cancer treatment, optional in combination with another existing cancer treatment. The present invention provides strategies to counteract tumor-induced immune tolerance and enhance the antitumor efficacy of chemotherapy by activating and leveraging T cell-mediated adaptive antitumor immunity against resistant or disseminated cancer cells.

1. A method for extending the progression-free survival or overall survival of a cancer patient, the method comprising the following steps: determining whether the cancer has a surrounding microenvironment that is favorable for immune modulation; determining whether the chemotherapy regimen induces immunogenic cell death; and if both are positive, administering an effective amount of a CDK4 / 6 inhibitor compound selected from I, II, III, IV, or V, or a pharmaceutically acceptable salt thereof, prior to administration of the chemotherapy or, optionally, prior to and concurrently with the chemotherapy, wherein the extension of the progression-free survival or overall survival is compared to the progression-free survival or overall survival based on administration of chemotherapy alone, based either on literature or otherwise published evidence, comparisons in preclinical or clinical trials, or other means recognized by those skilled in the art.

The present invention addresses the problem of providing a novel means for treating cancer by activating antitumor immunity in cancer cells. The present invention provides an antitumor immunity induction method comprising introducing a virus-derived gene or a gene whose expression is induced by the virus-derived gene into a cancer cell.